| dbo:abstract
|
- Buserelin, sold under the brand name Suprefact among others, is a medication which is used primarily in the treatment of prostate cancer and endometriosis. It is also used for other indications such as the treatment of premenopausal breast cancer, uterine fibroids, and early puberty, in assisted reproduction for female infertility, and as a part of transgender hormone therapy. In addition, buserelin is used in veterinary medicine. The medication is typically used as a nasal spray three times per day, but is also available for use as a solution or implant for injection into fat. Side effects of buserelin are related to sex hormone deprivation and include symptoms of low testosterone levels and low estrogen levels such as hot flashes, sexual dysfunction, vaginal atrophy, and osteoporosis. Buserelin is a gonadotropin-releasing hormone agonist (GnRH agonist) and works by preventing the production of sex hormones by the gonads. It can lower sex hormone levels by about 95% in both sexes. Buserelin is a peptide and an analogue of GnRH. Buserelin was first patented in 1974 and approved for medical use in 1985. It is not available in the United States, but is marketed widely elsewhere in the world, including in the United Kingdom, Canada, and many other countries. The medication is one of only two medically used GnRH analogues that are available as nasal sprays, the other being nafarelin. Buserelin is available as a generic medication. (en)
- Buserelin ist die Abkürzung für Butylserylrelin und beschreibt einen hormonell wirksamen Arzneistoff, der als GnRH-Analogon wirkt. (de)
- La buserelina è un ormone di rilascio delle gonadotropine ed è un agonista del GnRH. Il buserelin acetato è commercializzato da Sanofi-Aventis con il marchio Suprefact ma è anche disponibile il generico. (it)
- Buserelina é um fármaco. Promove a estimulação da produção do hormônio luteinizante (LH) e do hormônio folículo-estimulante (FSH). É utilizado como anticoncepcional, na endometriose e no carcinoma de próstata. (pt)
- Buserelinacetat är det vanligaste medlet i den grupp läkemedel som på engelska kallas Gonadotropin releasing hormone analogue, GnRH-analoger. I Sverige säljs buserelinacetet under handelsnamnet Receptal (veterinärmedicinskt) respektive Suprefact (medicinskt). Medlen är syntetiska peptidpreparat utformade med hormonet GnRH, som utsöndras från hypotalamus, som modell. Dess främsta användningsområde hos människor är som behandling vid prostatacancer, då medlet minskar testosteronhalten hos män. (sv)
- Бусерелін (англ. Buserelin, лат. Buserelinum) — синтетичний лікарський препарат, який за своєю хімічною будовою є поліпептидом та аналогом гонадотропін-рилізинг гормону, та застосовується як перорально, так і внутрішньом'язово, підшкірно та внутрішньовенно, а також інтраназально. Бусерелін синтезований у 1976 році, та застосовується у клінічній практиці з 1984 року. (uk)
|
| dbo:alternativeName
| |
| dbo:casNumber
|
- 57982-77-1
- 68630-75-1 (acetate)
|
| dbo:chEBI
| |
| dbo:chEMBL
| |
| dbo:class
| |
| dbo:drugbank
| |
| dbo:fdaUniiCode
| |
| dbo:pubchem
| |
| dbo:thumbnail
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 35430 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:atcSuffix
| |
| dbp:bioavailability
|
- Intranasal: 2.5–3.3% (en)
- Oral: ineffective (en)
- Subcutaneous: 70% (en)
|
| dbp:c
| |
| dbp:casNumber
| |
| dbp:casSupplemental
| |
| dbp:chebi
| |
| dbp:chembl
| |
| dbp:chemspiderid
| |
| dbp:class
| |
| dbp:drugbank
| |
| dbp:eliminationHalfLife
| |
| dbp:excretion
| |
| dbp:h
| |
| dbp:image
|
- Buserelin molecule ball.png (en)
|
| dbp:iupacName
|
- -N-[-1-[[-1-[[-1-[[-1-[[-1-[[-1-[[-5--1-[-2-pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[oxy]-1-oxopropan-2-yl]amino]-3--1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3--1-oxopropan-2-yl]amino]-3--1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide (en)
|
| dbp:iupharLigand
| |
| dbp:legalStatus
| |
| dbp:metabolism
|
- Liver, kidneys, gastrointestinal tract (en)
|
| dbp:metabolites
| |
| dbp:n
| |
| dbp:o
| |
| dbp:pregnancyCategory
| |
| dbp:proteinBound
| |
| dbp:pubchem
| |
| dbp:routesOfAdministration
| |
| dbp:smiles
|
- CCNC[C@@H]1CCCN1C[C@H]NC[C@H]NC[C@@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@@H]6CCCN6 (en)
|
| dbp:stdinchi
| |
| dbp:stdinchikey
|
- CUWODFFVMXJOKD-UVLQAERKSA-N (en)
|
| dbp:synonyms
|
- Etilamide; HOE-766; HOE-766A; ICI-123215; S-746766; (D)-Ser6EA10-LHRH; 6-[O--(D)-serine]-9--10-deglycinamide-LHRH (en)
|
| dbp:tradename
| |
| dbp:unii
| |
| dbp:verifiedfields
| |
| dbp:verifiedrevid
| |
| dbp:watchedfields
| |
| dbp:width
|
- 225 (xsd:integer)
- 235 (xsd:integer)
|
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- Buserelin ist die Abkürzung für Butylserylrelin und beschreibt einen hormonell wirksamen Arzneistoff, der als GnRH-Analogon wirkt. (de)
- La buserelina è un ormone di rilascio delle gonadotropine ed è un agonista del GnRH. Il buserelin acetato è commercializzato da Sanofi-Aventis con il marchio Suprefact ma è anche disponibile il generico. (it)
- Buserelina é um fármaco. Promove a estimulação da produção do hormônio luteinizante (LH) e do hormônio folículo-estimulante (FSH). É utilizado como anticoncepcional, na endometriose e no carcinoma de próstata. (pt)
- Buserelinacetat är det vanligaste medlet i den grupp läkemedel som på engelska kallas Gonadotropin releasing hormone analogue, GnRH-analoger. I Sverige säljs buserelinacetet under handelsnamnet Receptal (veterinärmedicinskt) respektive Suprefact (medicinskt). Medlen är syntetiska peptidpreparat utformade med hormonet GnRH, som utsöndras från hypotalamus, som modell. Dess främsta användningsområde hos människor är som behandling vid prostatacancer, då medlet minskar testosteronhalten hos män. (sv)
- Бусерелін (англ. Buserelin, лат. Buserelinum) — синтетичний лікарський препарат, який за своєю хімічною будовою є поліпептидом та аналогом гонадотропін-рилізинг гормону, та застосовується як перорально, так і внутрішньом'язово, підшкірно та внутрішньовенно, а також інтраназально. Бусерелін синтезований у 1976 році, та застосовується у клінічній практиці з 1984 року. (uk)
- Buserelin, sold under the brand name Suprefact among others, is a medication which is used primarily in the treatment of prostate cancer and endometriosis. It is also used for other indications such as the treatment of premenopausal breast cancer, uterine fibroids, and early puberty, in assisted reproduction for female infertility, and as a part of transgender hormone therapy. In addition, buserelin is used in veterinary medicine. The medication is typically used as a nasal spray three times per day, but is also available for use as a solution or implant for injection into fat. (en)
|
| rdfs:label
|
- Buserelin (en)
- Buserelin (de)
- Buserelina (it)
- Buserelina (pt)
- Бусерелін (uk)
- Buserelinacetat (sv)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
